[ENG] QOL-ONE III ANNUAL CONFERENCE SINDROMI MIELODISPLASTICHE E COMPLICANZE 29 Settembre 2018

Usern Congress and Prize Festival – Reggio Calabria (Italy) November 10th 2018 -Mediterranea University – Reggio Calabria

Qol-One investigator Meeting on Rev2MDS Trial @ASH – Dec. 11 2017

By invitation only. To discus Rev2MDS (Efficacy of eltrombopag plus Lenalidomide combination therapy in patients with IPSS low and intermediate-risk myelodysplastic syndrome with isolated del5q: a multicenter, randomized, double-blind, placebo controlled study).

Collaboration Room Number 26 in Hall B1.